Ocular Therapeutix, which develops eye therapies using a sustained-release hydrogel platform, raised $65 million by offering 5 million shares at $13, below the range of $14 to $16. Ocular Therapeutix plans to list on the NASDAQ under the symbol OCUL. Ocular Therapeutix initially filed confidentially on 4/29/2014. Morgan Stanley, Cowen & Company and RBC Capital Markets acted as lead managers on the deal.
